Merck & Co., Inc.
Merck is developing MK-7602, a novel antimalarial candidate being evaluated alone and planned for use in a fixed-dose combination with pyronaridine for the treatment of uncomplicated P. falciparum malaria.
What they do
Merck is developing MK-7602, a novel antimalarial candidate being evaluated alone and planned for use in a fixed-dose combination with pyronaridine for the treatment of uncomplicated P. falciparum malaria.1 Its U.S. malaria R&D is distributed across Merck sites in Rahway, New Jersey; Upper Gwynedd, Pennsylvania; and West Point, Pennsylvania.1 Its malaria work is in the development stage.1 Multiple Phase 1 studies, including single- and multiple-ascending-dose studies and a controlled human malaria infection study, have been completed, and a Phase 2 study in Kenya and Uganda is planned to begin in the first half of 2027.1
- Rahway, NJ1Headquarters · Research and development
- Upper Gwynedd, PA1Research and development
- West Point, PA1Research and development
In the field and in development
Partnerships in 2 endemic countries
Who they work with in the United States
- In the atlas
Where this comes from
- 1Confirmed by the organization
- 2clinicaltrials.gov
- 3merck.com